Skip to content

Coenzyme q 10 and Fertility Outcome in Women With Clomiphene Resistant PCOS

Combined Coenzyme Q10 and Clomiphene Citrate for Ovulation Induction in Clomiphene-citrate-resistant Polycystic Ovary Syndrome

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04302532
Enrollment
149
Registered
2020-03-10
Start date
2020-07-01
Completion date
2020-10-30
Last updated
2020-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coenzyme q10

Keywords

ovulation induction, coenzyme q10, pregnancy rate

Brief summary

The study evaluates the effect of coenzyme q 10 on ovulation and subsequent pregnancy in women with polycystic ovarian syndrome. Half of the participants will receive coq10 and ovulation induction with clomiphene and other half would receive a placebo with clomiphene.

Interventions

DRUGCoenzyme Q10

antioxidant used to decrease oxidative stress and improve fertility prospects

DRUGclomiphene citrate

ovulation induction drug

Sponsors

Karachi Medical and Dental College
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of polycystic ovarian syndrome PCOS based on the revised 2003 consensus on diagnostic criteria and long-term health risks related to PCOS (2003). * All women were previously treated with 100 mg of CC daily for 5 days per cycle, for two to three cycles with persistent anovulation or ovulate with very thin endometrium \<5 mm at the time of hCG administration

Exclusion criteria

* Non-consenting. * known autoimmune disorders * prior treatment of endometriosis or surgery to reproductive tract * prior history of pelvic inflammatory disease * those with tubal factors and uterine factors as assessed on history and confirmed by normal hysterosalpingogram. * Thyroid disorder as assessed by history examination and TSH level * Patients with raised FSH

Design outcomes

Primary

MeasureTime frameDescription
number of ovulating women1-2 monthstransvaginal ultrasound as the disappearance of the leading follicle, presence of follicular fluid in the Douglas pouch and midluteal progesterone \>5 pg/ml.
number of pregnancies1-2 monthsultrasound visualization of gestational sac with pulsating fetal pole

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026